The Anti-myocardial Fibrosis Effect of Vericiguat in HFrEF - Trial NCT05799638
Access comprehensive clinical trial information for NCT05799638 through Pure Global AI's free database. This Phase 4 trial is sponsored by Chongqing Medical University and is currently Recruiting. The study focuses on Heart Failure With Reduced Ejection Fraction. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Chongqing Medical University
Timeline & Enrollment
Phase 4
Apr 01, 2023
Jun 01, 2024
Primary Outcome
Extracellular volume [ECV]
Summary
Vericiguat is a new medication therapy choice for the patients with heart failure with
 reduced ejection fraction (HFrEF), in the latest trial, it met the expectation to reduce
 incidence of death from cardiovascular causes or hospitalization for heart failure among
 HFrEF patients. Myocardial fibrosis as a pathological change in heart failure, it contributes
 to left ventricular dysfunction leading to development of the disease, experimental studies
 have showed the potential prevention, or even reversal effect of sGC stimulators in left
 ventricular hypertrophy and fibrosis. Our study is a prospective controlled clinical trial
 aim to verify the anti-myocardial fibrosis effect of vericiguat in heart failure with reduced
 ejection fraction.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05799638
Non-Device Trial